Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 21;24(19):3433.
doi: 10.3390/molecules24193433.

Investigation of 5'-Norcarbocyclic Nucleoside Analogues as Antiprotozoal and Antibacterial Agents

Anastasia L Khandazhinskaya  1 , Elena S Matyugina  2 , Pavel N Solyev  3 , Maggie Wilkinson  4 , Karen W Buckheit  5 , Robert W Buckheit Jr  6 , Larisa N Chernousova  7 , Tatiana G Smirnova  8 , Sofya N Andreevskaya  9 , Khalid J Alzahrani  10 , Manal J Natto  11 , Sergey N Kochetkov  12 , Harry P de Koning  13 , Katherine L Seley-Radtke  14
Affiliations

Investigation of 5'-Norcarbocyclic Nucleoside Analogues as Antiprotozoal and Antibacterial Agents

Anastasia L Khandazhinskaya et al. Molecules. .

Abstract

Carbocyclic nucleosides have long played a role in antiviral, antiparasitic, and antibacterial therapies. Recent results from our laboratories from two structurally related scaffolds have shown promising activity against both Mycobacterium tuberculosis and several parasitic strains. As a result, a small structure activity relationship study was designed to further probe their activity and potential. Their synthesis and the results of the subsequent biological activity are reported herein.

Keywords: antiparasitic; carbocyclic; leishmanial; mycobacterial; nucleosides; tuberculosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Some historically important carbocyclic nucleosides.
Figure 2
Figure 2
Previous leads.
Figure 3
Figure 3
Target compounds.
Scheme 1
Scheme 1
Synthesis of the target compounds.
See this image and copyright information in PMC

References

    1. Seley-Radtke K.L., Yates M.K. The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold. Antiviral Res. 2018;154:66–86. doi: 10.1016/j.antiviral.2018.04.004. - DOI - PMC - PubMed
    1. Yates M.K., Seley-Radtke K.L. The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold. Antivir. Res. 2019;162:5–21. doi: 10.1016/j.antiviral.2018.11.016. - DOI - PMC - PubMed
    1. Matyugina E.S., Khandazhinskaya A.L., Kochetkov S.N. Carbocyclic nucleoside analogues: Classification, target enzymes, mechanisms of action and synthesis. Russ. Chem. Rev. 2012;81:729–746. doi: 10.1070/RC2012v081n08ABEH004314. - DOI
    1. Matyugina E.S., Valuev-Elliston V.T., Babkov D.A., Novikov M.S., Ivanov A.V., Kochetkov S.N., Balzarini J., Seley-Radtke K.L., Khandazhinskaya A.L. 5′-Nor carbocyclic nucleosides: Unusual nonnucleoside inhibitors of HIV-1 reverse transcriptase. Medchemcomm. 2013;4:741–748. doi: 10.1039/c3md00036b. - DOI
    1. Matyugina E.S., Valuev-Elliston V.T., Geisman A.N., Novikov M.S., Chizhov A.O., Kochetkov S.N., Seley-Radtke K.L., Khandazhinskaya A.L. Structure-activity evaluation of new uracil-based non-nucleoside inhibitors of HIV reverse transcriptase. Medchemcomm. 2013;4:1443–1451. doi: 10.1039/c3md00225j. - DOI

MeSH terms